Infectious causes of cancer

CarraShield Labs Issued Ground-breaking Patent for Anti-viral Gel Technology Used to Prevent HPV Infections

Wednesday, September 23, 2020 - 4:00pm

CarraShield Labs' patented gel technology was first tested in groundbreaking work at the National Cancer Institute.

Key Points: 
  • CarraShield Labs' patented gel technology was first tested in groundbreaking work at the National Cancer Institute.
  • The CarraShield gel technology opens up entirely new ways to help prevent HPV-induced cancers and warts above and beyond vaccines.
  • Current HPV vaccines only protect against up to 9 types of HPV virus out of over 200 HPV types.
  • The first product to contain CarraShield is Divine 9, a water-based personal lubricant used to help prevent HPV infections in women.

Clinical Genomics Announces Publication of Additional Clinical Data for COLVERA® Recurrence monitoring Blood Test for Colorectal Cancer Patients

Tuesday, September 22, 2020 - 1:00pm

This U.S. population study further reinforces the performance of COLVERA, the breakthrough blood test for the clinical presence of CRC recurrence in patients amenable to curative intent.

Key Points: 
  • This U.S. population study further reinforces the performance of COLVERA, the breakthrough blood test for the clinical presence of CRC recurrence in patients amenable to curative intent.
  • COLVERA therefore represents an important advance over the current standard of care for colorectal cancer surveillance.
  • Clinical Genomics products span the full spectrum of colorectal cancer testing from screening to post-treatment monitoring.
  • COLVERA is the first of its kind blood test to detect circulating tumor DNA for minimal residual disease (MRD) assessment and recurrence monitoring in patients previously diagnosed with colorectal cancer.

COVID-19 Recovery Analysis: Helicobacter Pylori Diagnostics Market | Resistance Of H. Pylori To Antibiotics to boost the Market Growth | Technavio

Tuesday, September 22, 2020 - 11:15am

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • View the full release here: https://www.businesswire.com/news/home/20200922005138/en/
    Technavio has announced its latest market research report titled Global Helicobacter Pylori Diagnostics Market 2020-2024 (Graphic: Business Wire)
    Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied.
  • Resistance of H. Pylori to antibiotics has been instrumental in driving the growth of the market.
  • Download a Free Sample Report on COVID-19 Impacts
    Helicobacter Pylori Diagnostics Market 2020-2024: Segmentation
    Helicobacter Pylori Diagnostics Market is segmented as below:

Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020

Sunday, September 20, 2020 - 1:25pm

KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

Key Points: 
  • KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
  • The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established.
  • Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or recurrent Grade 2 pneumonitis.
  • Administer corticosteroids for Grade 2 or greater hepatitis and, based on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA.

Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting

Friday, September 18, 2020 - 2:03pm

Natera will present four abstracts one oral and three poster presentations which highlight applications for detecting MRD levels and tracking tumor clonal evolution in CRC and in esophageal adenocarcinoma.

Key Points: 
  • Natera will present four abstracts one oral and three poster presentations which highlight applications for detecting MRD levels and tracking tumor clonal evolution in CRC and in esophageal adenocarcinoma.
  • "We're delighted to share new data at this year's ESMO meeting, which shows the broad potential of our tumor-informed approach to MRD assessment," said Alexey Aleshin, M.D., M.B.A., Senior Medical Director of Oncology at Natera.
  • "These studies demonstrate that Signatera provides clinically actionable information that can improve the management of patients with multiple different solid cancers."
  • Signatera test performance has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers.

Agenus Initiates Rolling BLA Submission of Balstilimab for Recurrent/Metastatic Cervical Cancer

Friday, September 18, 2020 - 1:30pm

Balstilimab is a novel anti-PD-1 human monoclonal antibody that has demonstrated promising clinical benefit in second line treatment of cervical cancer.

Key Points: 
  • Balstilimab is a novel anti-PD-1 human monoclonal antibody that has demonstrated promising clinical benefit in second line treatment of cervical cancer.
  • The initiation of the rolling BLA is an exciting step forward for Agenus as we are closer to making our therapies commercially available for patients with cervical cancer who have limited treatment options available, said Dr. Jennifer Buell, President and COO of Agenus.
  • A rolling submission allows Agenus to submit each section of the BLA as it is completed, which enables the FDA to review the submitted sections in parallel with Agenuss completion of the balance of the BLA application.
  • The American Cancer Society estimates around 14,000 new cases of invasive cervical cancer to be diagnosed this year and nearly 4,300 cervical cancer deaths.

Global Helicobacter Pylori Diagnostics Market (2020 to 2024) - Featuring Abbott Laboratories, bioMerieux & Quest Diagnostics Among Others - ResearchAndMarkets.com

Friday, September 18, 2020 - 11:37am

The "Global Helicobacter Pylori Diagnostics Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Helicobacter Pylori Diagnostics Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • The helicobacter pylori diagnostics market is poised to grow by $ 209.59 million during 2020-2024 progressing at a CAGR of 8% during the forecast period.
  • The reports on helicobacter pylori diagnostics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • This study identifies the rising prevalence of disease as one of the prime reasons driving the helicobacter pylori diagnostics market growth during the next few years.

Cervical Cancer Market is Expected to Increase With a CAGR of 16.9% for the Study Period of 2017-2030 in 7MM: DelveInsight

Thursday, September 17, 2020 - 3:30pm

An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.

Key Points: 
  • An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.
  • Some of the key insights from cervical cancer market report:
    The incidence of cervical cancer in 7MM (US, UK, Germany, Italy, Spain, France & Japan) in 2020 is expected to be 43,712.
  • Get a cervical cancer sample copy or download a cervical cancer infograph: www.delveinsight.com/sample-request/cervical-cancer-market
    Cervical cancer is a cause of infection from Human papillomavirus (HPV), which can be prevented.
  • The cervical cancer market also homes Merck's star, Keytruda, which got approval in 2018 for advanced cervical cancer for PD-L1 positive patients.

Cervical Cancer Market is Expected to Increase With a CAGR of 16.9% for the Study Period of 2017-2030 in 7MM: DelveInsight

Thursday, September 17, 2020 - 3:30pm

An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.

Key Points: 
  • An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.
  • Some of the key insights from cervical cancer market report:
    The incidence of cervical cancer in 7MM (US, UK, Germany, Italy, Spain, France & Japan) in 2020 is expected to be 43,712.
  • Get a cervical cancer sample copy or download a cervical cancer infograph: www.delveinsight.com/sample-request/cervical-cancer-market
    Cervical cancer is a cause of infection from Human papillomavirus (HPV), which can be prevented.
  • The cervical cancer market also homes Merck's star, Keytruda, which got approval in 2018 for advanced cervical cancer for PD-L1 positive patients.

Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

Thursday, September 17, 2020 - 11:30am

At the time of analysis, 114 patients with advanced cancers had been treated with cosibelimab and were evaluable for safety.

Key Points: 
  • At the time of analysis, 114 patients with advanced cancers had been treated with cosibelimab and were evaluable for safety.
  • Cosibelimab appeared to be safe and well-tolerated with a potentially favorable safety profile as compared to currently available anti-PD-1 therapies.
  • The trial continues to enroll patients, and full top-line results are expected in mid-2021.
  • Cutaneous squamous cell carcinoma (CSCC) is the second most common human cancer in the United States, with an estimated annual incidence of 700,000 cases.